Read this company snapshot
Daily valuation snapshot
MeiraGTx Holdings plc Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $10.69
- Market capitalization (USD)
- $1,026,699,627.24
- Price / earnings (TTM)
- 13
- Price / book
- 4.76
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research MGTX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research MGTX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing MGTX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $10.69 |
| Market capitalization (USD) | $1,026,699,627.24 |
| Price / earnings (TTM) | 13 |
| Price / book | 4.76 |
No matching rows. Clear the filter to see all records.
Read MGTX's valuation metrics
Company size
MeiraGTx Holdings plc Ordinary Shares's recorded market capitalization is $1,026,699,627.24. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
MGTX's recorded P/E is 13: about $13 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
MGTX's recorded price-to-book ratio is 4.76. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research MeiraGTx Holdings plc Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about MGTX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow MGTX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.